[Clinical studies on sulbactam/cefoperazone in pediatric field].
Clinical studies on sulbactam/cefoperazone (SBT/CPZ) were carried out and the results were as follows: Eleven patients (pneumonia 8, acute purulent arthritis of the knee joint 1, urinary tract infection 2) were treated with SBT/CPZ, in doses of 30-67 mg/kg divided 3 times per day for 3-61/3 days intravenously. The overall efficacy rate was 100%. As to adverse reaction, diarrhea was observed in 1 case. Abnormal laboratory data were noted in 2 cases (GPT elevation in 1, and eosinophilia and GPT elevation in 1).
D000367:Age Factors; D001424:Bacterial Infections / Q000188:drug therapy*; D002438:Cefoperazone / Q000008:administration & dosage*; D002675:Child, Preschool; D004338:Drug Combinations; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D007223:Infant; D007263:Infusions, Parenteral; D007275:Injections, Intravenous; D008297:Male; D010397:Penicillanic Acid / Q000008:administration & dosage*; D013407:Sulbactam; D065093:beta-Lactamase Inhibitors
D004338:Drug Combinations; D065093:beta-Lactamase Inhibitors; D002438:Cefoperazone; D010397:Penicillanic Acid; D013407:Sulbactam